SAGE Therapeutics (SAGE) Misses Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to SAGE Therapeutics (SAGE) Misses Q3 EPS by 21c

Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

November 6, 2018 6:30 AM EST

FDA Advisory Committee Meeting outcome supports approval of ZULRESSO (brexanolone) injection as the first medicine specifically indicated for the treatment of postpartum depression (PPD)

Continuing to execute commercial strategy for ZULRESSO in PPD ahead of PDUFA target date of December 19, 2018 and readiness for planned U.S. launch in late March

Completion of enrollment in Phase 3 clinical trial of SAGE-217 in PPD top-line results expected in January 2019

Expansion of depression franchise with initiation of Phase 2 clinical trial of SAGE-217 in bipolar depression and multiple near-term trial initiations... More